Search

Displaying results 5671 - 5680 of 7018 in total
  1. Drug

    {[5-(5-nitro-2-furyl)-1,3,4-oxadiazol-2-yl]thio}acetic acid

    go.drugbank.com/drugs/DB08098
    Experimental

    These are compounds containing a furan ring which bears a nitro group. It targets the protein aldose reductase.

  2. Drug

    Dirithromycin

    go.drugbank.com/drugs/DB00954
    Investigational

    Dirithromycin is a macrolide glycopeptide antibiotic used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections.

  3. Drug

    ADVM-062

    go.drugbank.com/drugs/DB18341
    Experimental

    ADVM-062 is an adeno-associated virus vector carrying complementary deoxyribonucleic acid encoding the human long-wave-sensitive opsin 1 (AAV.7m8-L-opsin)

  4. Drug

    Dipraglurant

    go.drugbank.com/drugs/DB12733
    Investigational

    It is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM).

  5. Drug

    Valiltramiprosate

    go.drugbank.com/drugs/DB19191
    Investigational

    Valiltramiprosate is under investigation in clinical trial NCT06304883 (Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects).

  6. Drug

    Peldesine

    go.drugbank.com/drugs/DB02568
    Investigational

    Peldesine is a potent inhibitor of human CCRF-CEM T-cell proliferation. It has undergone phase I trials for the treatment of Human Immunodeficiency Virus (HIV) infections.

  7. Drug

    Talopram

    go.drugbank.com/drugs/DB09190
    Experimental

    Talopram is a selective norepinephrine reuptake inhibitor (SNRI) that is structurally similar to citalopram and melitracen. It was researched in the 1960s and 1970s but never marketed.

  8. Drug

    MRK-003

    go.drugbank.com/drugs/DB17015
    Experimental

    MRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of [MK-0752], a drug in clinical development.[A252682]

  9. Drug

    ICG-136

    go.drugbank.com/drugs/DB17343
    Experimental

    ICG-136 is a compound chimeric antigen receptor (cCAR) T-cell therapy developed by iCell Gene Therapeutics. It was investigated for the treatment of acute myeloid leukemia.

    Synonyms: CD123-CD33cCAR T-cells, ICG136:CD123-CD33cCAR T-cells
  10. Drug

    IO-202

    go.drugbank.com/drugs/DB17548
    Investigational

    IO-202 is a first-in-class antibody targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) member 4 (LILRB4).[A257276] It is being investigated in cancers.